DRUG
Tirzepatide
Administered SC
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Status
Recruiting
Phase
Phase 4
Enrollment
3,000
Locations
30
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
Interventions
Treatment arms and agents.
OTHER
Standard of Care
Standard of care
Timeline
From registration to results.
First posted
Nov 25, 2025
Study start
Nov 24, 2025
Primary completion
Jul 2029
Study completion
Jul 2032
Results posted
Not reported
Registry updated
Jul 7, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, 24 months
Secondary outcomes
Time from Baseline to Onset of Type 2 Diabetes
Time frame · Baseline through 60 months
Percentage of Participants Converting from Prediabetes to Normoglycemia
Time frame · 60 months
Percentage of Participants with Normoglycemia at Baseline who Develop Prediabetes
Time frame · 60 months
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame · Baseline, 60 months
Percentage of Participants who Develop a New Obesity-Related Complication
Time frame · 60 months
Change from Baseline in Waist Circumference
Time frame · Baseline, 60 months
Change from Baseline in Waist-to-Height Ratio
Time frame · Baseline, 60 months
Change from Baseline in Total Cholesterol
Time frame · Baseline, 60 months
Change from Baseline in Systolic Blood Pressure
Time frame · Baseline, 60 months
Change from Baseline in Diastolic Blood Pressure
Time frame · Baseline, 60 months
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Study locations
30 registered sites.
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
P91604 St John's Medical Centre
Altrincham, United Kingdom
P89008 Ashton Medical Group
Ashton-under-Lyne, United Kingdom
Y02319 SSP Bolton General Practice
Bolton, United Kingdom
P83012 Tower Family Healthcare
Bury, United Kingdom
P91014 Washway Road Medical Centre
Cheshire, United Kingdom
P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House)
Cheshire, United Kingdom
Y02790 SSP Bolton Medical Centre
Great Lever, United Kingdom
P89002 The Brooke Surgery
Hyde SK14, United Kingdom
P84035 Bodey Medical Centre
Manchester, United Kingdom
P84630 The Arch Medical Practice
Manchester, United Kingdom
P84678 Didsbury Medical Centre
Manchester, United Kingdom
P84017 Ladybarn Group Practice
Manchester, United Kingdom
P84068 Chorlton Family Practice
Manchester, United Kingdom
P84012 Northenden Group Practice
Manchester, United Kingdom
P86004 Peterloo Medical Centre
Manchester, United Kingdom
P83025 St Gabriels Medical Centre
Manchester, United Kingdom
P87019 Silverdale Medical Practice
Manchester, United Kingdom
P91006 Urmston Group Practice
Manchester, United Kingdom
P92620 SSP Ince Surgery (Lower Ince)
Manchester, United Kingdom
P84034 Barlow Medical Centre
Manchester, United Kingdom
P85010 Woodlands Medical Practice
Oldham, United Kingdom
P85011 CH Medical Practice
Oldham, United Kingdom
P86022 Stonefield Street Surgery
Rochdale, United Kingdom
P91021 Firsway Health Centre
Sale, United Kingdom
Related trials
More studies on Tirzepatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.